In pursuit of a blockbuster, Amgen and AstraZeneca score priority review for asthma drug tezepelumab
Amgen and AstraZeneca are one big step closer to realizing their blockbuster dreams for tezepelumab after the FDA granted a priority review for the asthma drug.
Despite the challenge of battling Regeneron and Sanofi’s Dupixent, tezepelumab has been pegged for peak sales of $2.5 billion. With AstraZeneca leading development, Amgen spearheading manufacturing and both sharing commercialization responsibilities, the two pharma giants have been vocal about their optimism.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.